Colorado-based remote patient monitoring company BioIntelliSense on Tuesday announced the acquisition of AlertWatch, a patient monitoring platform.
AlertWatch aggregates data and provides clinicians with a composite view of patient vital sign trends.
The company received four FDA 510(k) clearances for its product offerings for the operating room, labor and delivery unit, and intensive care unit. AlertWatch is also used in general care wards and with at-home care.
BioIntelliSense will add AlertWatch to its HealthCast portfolio and integrate the platform with its BioButton wearable, a product used for continuous vital sign monitoring for 60 days that captures temperature, respiratory rate and heart rate at rest.
“The addition of AlertWatch offers healthcare providers comprehensive continuous monitoring solutions, and an accelerated path from adoption to full scale utilization. The patented AlertWatch multi-parameter interface displays and analyzes data from inpatient vitals, the electronic medical record (EMR), laboratory systems and BioIntelliSense medical-grade wearables, to provide clinical intelligence across care settings and acuity levels,” Dr. James Mault, founder and CEO of BioIntelliSense, said in an email.
THE LARGER TREND
AlertWatch is a new addition to BioIntelliSense’s patient monitoring portfolio, which includes wearable products that allow clinicians to collect patient data outside the hospital.
BioIntelliSense’s tools include BioSticker, a body sticker that captures medical data and analytics with early detection capabilities, and BioButton, a product used for continuous vital sign monitoring. The company announced a $45 million Series B raise last year.
In August, it announced a strategic partnership with Medtronic for the U.S. hospital and 30-day post-acute home distribution rights for BioButton. AlertWatch will now be integrated with the BioButton wearable, and be available through Medtronic as well.